


Pembrolizumab KEYNOTE-012


PRELIMINARY SCORE

CURATIVE



NON-CURATIVE

PFS



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Pembrolizumab KEYNOTE-012

FINAL SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival


1



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Head and neck cancer  
Therapeutic Indication: Recurrent or metastatic SCCHN with disease progression on or after platinum-containing ChT  
Experimental Arm: Pembrolizumab  
Control Arm: Single arm

